ClinicalTrials.gg
RecruitingNCT07493538Updated Apr 16, 2026

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

A Phase 2 interventional study of Treosulfan and Fludarabine in AML, MDS and Acute Leukemia, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing treosulfan in Leukemia, Myeloid, Acute — 4 open to participants now, 5 under way, none of them phase 3. treosulfan · Leukemia, Myeloid, Acute.

Planned enrollment
3rd of 14
132 · median 68
Started
2026
with 2 others
Phase 2
11 of 14
4 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Masonic Cancer Center, University of Minnesota

Among the 14 studies testing treosulfan in Leukemia, Myeloid, Acute, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 11 in phase 2, and was the 14th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 14 studies testing treosulfan in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treosulfan

treosulfan: first FDA approval 2025 (GRAFAPEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing treosulfan in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

03

Conditions studied

  • AML
  • MDS
  • Acute Leukemia
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 2-75 years of age
  • ≤7 5 years of age: score ≥ 70% (≥ 16 years) or Lansky play score ≥ 50 (\< 16 years) with appropriate organ criteria as below (in other inclusion criteria)
  • 5/6 or 6/6 related donor, OR a 5-8/8 HLA-A, B, C, DRB1 allele match unrelated donor, OR a haplotype (at least 5/10) related donor
  • adequate liver (no decompensated liver failure, A, /ALT \<5X ) and renal function (creatinine \<2.0)
  • absence of decompensated congestive heart failure, or uncontrolled arrhythmia and ≥ 40%
  • DLCO , FVC ≥ 40% predicted, and absence of O2 requirement

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Evidence of untreated/uncontrolled infection
  • Untreated active serious infection
  • Active CNS
  • CML in blast crisis not in a complete remission by abnormal blast count.
  • Less than 3 months since prior myeloablative transplant
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Treo/Flu with PTCy

    Subjects treated with Treosulfan and Fludarabine preparative regimen with TBI for AML and MDS patients followed by a related or unrelated donor stem cell infusion utilizing PTCy, tacrolimus and MMF as GVHD prophylaxis.

    Drug: Treosulfan · Drug: Fludarabine · Radiation: Total Body Irradiation · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Drug: Cyclophosphamid · Biological: Stem Cell Infusion

Interventions

  • 12 g/m2 administered intravenously over 2 hours on days -4, -3, and -2.

  • Fludarabine will be administered intravenously over 1 hour, every 24 hours on days -6 to -2. The daily dose of fludarabine will be determined by model-based dosing utilizing Bayesian methodology .

  • RadiationTotal Body Irradiation

    TBI 200 cGy will be administered as a single treatment on day -1 per current institutional guidelines.

    Also known as: TBI

  • Tacrolimus may be initiated on day +5 either PO or IV gtt , with a goal trough level of 5-10mg/mL and avoiding higher levels for the first two weeks post-transplant, as recent evidence demonstrated increased adverse events for levels over 10 mg/mL.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients begin mycophenolate mofetil (MMF) day +5 through day +35 if no acute GVHD or 7 days after engraftment, whichever is later.

    Also known as: MMF

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide 40 mg/kg will be given as an IV infusion over 1-2 hours (depending on volume) on Days +3 post-transplant (between 60 and 72 hours after stem cell infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide).

  • BiologicalStem CellStudies of Stem CellStem Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given on day 0.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Evaluate rates of overall survival at 100 days after transplant.

    Time frame: Day 100

Secondary outcomes

  1. Transplant Related Mortality

    ● Estimate transplant related mortality (TRM) at 100 days and 1 year with this conditioning and GVHD prophylaxis combination

    Time frame: Day 100 and 1 year

  2. Overall Survival

    Estimate overall survival at 1 and 2 years

    Time frame: 1 and 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 47 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2035
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07493538
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 10, 2026
Primary completion
Mar 2030 (estimated)
Completion
Mar 2035 (estimated)
Last update
Apr 16, 2026

Study contacts

Christopher Graham, MD
Contact
grah0329@umn.edu
612-625-3051

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Treosulfan · Fludarabine · Stem Cell

Start the discussion